Freestone Grove Partners LP purchased a new stake in Humana Inc. (NYSE:HUM – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 51,390 shares of the insurance provider’s stock, valued at approximately $20,413,000.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Montag A & Associates Inc. grew its position in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after buying an additional 94 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of Humana during the 2nd quarter worth approximately $26,000. Fideuram Asset Management Ireland dac purchased a new stake in shares of Humana during the 4th quarter worth approximately $27,000. Trust Co. of Vermont acquired a new stake in shares of Humana in the 2nd quarter worth approximately $28,000. Finally, Reflection Asset Management purchased a new position in Humana in the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.
Humana Price Performance
Humana stock opened at $392.72 on Friday. The stock has a market capitalization of $47.16 billion, a P/E ratio of 37.15, a P/E/G ratio of 2.23 and a beta of 0.72. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $428.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. The firm’s 50-day moving average is $385.08 and its two-hundred day moving average is $287.78.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. HSBC downgraded Humana to a “hold” rating in a research report on Thursday, July 30th. Needham & Company LLC assumed coverage on Humana in a research note on Wednesday, May 20th. They set a “buy” rating for the company. Truist Financial boosted their price objective on shares of Humana from $320.00 to $415.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Morgan Stanley raised shares of Humana from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $249.00 to $370.00 in a research note on Tuesday, August 4th. Finally, Piper Sandler upgraded shares of Humana from a “hold” rating to an “overweight” rating and set a $463.00 target price for the company in a report on Thursday, July 30th. Fourteen research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $403.91.
View Our Latest Stock Analysis on HUM
Humana Profile
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Recommended Stories
- Five stocks we like better than Humana
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
